CoChat

Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial

Open access

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Abstract

Introduction: Recurrent pulmonary exacerbations lead to progressive lung damage in cystic fibrosis (CF). Inhaled medications (mucoactive agents and antibiotics) help prevent exacerbations, but objectively measured adherence is low. We investigated whether a multi-component (complex) self-management intervention to support adherence would reduce exacerbation rates over 12 months. Methods: Between October 2017 and May 2018, adults with CF (aged ≥16 years; 19 UK centres) were randomised to the intervention (data-logging nebulisers, a digital platform and behavioural change sessions with trained clinical interventionists) or usual care (data-logging nebulisers). Outcomes included pulmonary exacerbations (primary outcome), objectively measured adherence, body mass index (BMI), lung function (FEV 1) and Cystic Fibrosis Questionnaire-Revised (CFQ-R). Analyses were by intent to treat over 12 months. Results: Among intervention (n=304) and usual care (n=303) participants (51% female, median age 31 years), 88% completed 12-month follow-up. Mean exacerbation rate was 1.63/year with intervention and 1.77/year with usual care (adjusted ratio 0.96; 95% CI 0.83 to 1.12; p=0.64). Adjusted mean differences (95% CI) were in favour of the intervention versus usual care for objectively measured adherence (9.5% (8.6% to 10.4%)) and BMI (0.3 (0.1 to 0.6) kg/m 2), with no difference for %FEV 1(1.4 (−0.2 to 3.0)). Seven CFQ-R subscales showed no between-group difference, but treatment burden reduced for the intervention (3.9 (1.2 to 6.7) points). No intervention-related serious adverse events occurred. Conclusions: While pulmonary exacerbations and FEV 1 did not show statistically significant differences, the intervention achieved higher objectively measured adherence versus usual care. The adherence difference might be inadequate to influence exacerbations, though higher BMI and lower perceived CF treatment burden were observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/thoraxjnl-2021-217594

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schedule of intervention delivery: normal and ‘very high adherence’ pathways. Adherence level to reflect baseline was calculated using objectively measured effective adherence data from weeks 1 and 2, as stated in the ‘Methods’.
Figure 1 Schedule of intervention delivery: normal and ‘very high adherence’ pathways. Adherence level to reflect baseline was calculated using objectively measured effective adherence data from weeks 1 and 2, as stated in the ‘Methods’.CC BY · PubMed Central
Figure 2 Trial profile. *Exclusions due to missing covariates. †Adherence level to reflect the effect of intervention was calculated using objectively measured effective adherence data from week 3 (ie, from the point of intervention delivery) through to week 52 (ie, the end of the trial), as stated in the ‘Methods’ and ‘Results’. The intervention effect is best reflected by the cumulative adherence level throughout the trial period, similar to the approach of calculating cumulative exacerbation events throughout the trial. Though there were drop-outs during the trial, exacerbation data were available for all participants (expect for a participant who withdrew on the day of randomisation) since exacerbation events prior to drop-out were analysed. In a similar vein, adherence data available prior to the point of drop out were analysed as long as adherence data from week 3 onwards were available. Only 19 participants did not provide any adherence data from week 3 onwards, that is, adherence data were missing for outcome analysis among 19/607 (3%) of participants. Week-by-week breakdown of adherence data completeness is provided in online supplemental table 2.
Figure 2 Trial profile. *Exclusions due to missing covariates. †Adherence level to reflect the effect of intervention was calculated using objectively measured effective adherence data from week 3 (ie, from the point of intervention delivery) through to week 52 (ie, the end of the trial), as stated in the ‘Methods’ and ‘Results’. The intervention effect is best reflected by the cumulative adherence level throughout the trial period, similar to the approach of calculating cumulative exacerbation events throughout the trial. Though there were drop-outs during the trial, exacerbation data were available for all participants (expect for a participant who withdrew on the day of randomisation) since exacerbation events prior to drop-out were analysed. In a similar vein, adherence data available prior to the point of drop out were analysed as long as adherence data from week 3 onwards were available. Only 19 participants did not provide any adherence data from week 3 onwards, that is, adherence data were missing for outcome analysis among 19/607 (3%) of participants. Week-by-week breakdown of adherence data completeness is provided in online supplemental table 2.CC BY · PubMed Central
Figure 3 Medication adherence over 12 months, by randomised group (usual care n=295; intervention n=293). *Objectively measured effective adherence (sum of doses taken/sum of doses prescribed) was calculated on a weekly basis, with adjustments made against what may be considered an ideal treatment for effectiveness, as based on the following rules: all participants should receive at least a muco-active agent; and all participants with chronic Pseudomonas should receive at least both a mucoactive agent and an antibiotic. Adherence data were aggregated and plotted weekly for the purpose of detecting whether adherence is actually changing to smooth out daily fluctuations that may just be noise, for example, due to weekday versus weekend differences in adherence.40
Figure 3 Medication adherence over 12 months, by randomised group (usual care n=295; intervention n=293). *Objectively measured effective adherence (sum of doses taken/sum of doses prescribed) was calculated on a weekly basis, with adjustments made against what may be considered an ideal treatment for effectiveness, as based on the following rules: all participants should receive at least a muco-active agent; and all participants with chronic Pseudomonas should receive at least both a mucoactive agent and an antibiotic. Adherence data were aggregated and plotted weekly for the purpose of detecting whether adherence is actually changing to smooth out daily fluctuations that may just be noise, for example, due to weekday versus weekend differences in adherence.40CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

40 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 55

Metadata

Authors
Wildman, M. J., O’Cathain, A., Maguire, C., Arden, M. A., Hutchings, M., Bradley, J., Walters, S. J., Whelan, P., Ainsworth, J., Buchan, I., Mandefield, L., Sutton, L., Tappenden, P., Elliott, R. A., Hoo, Z. H., Drabble, S. J., & Beever, D.
Affiliations
  • Sheffield Teaching Hospitals NHS Foundation Trust (GB)
  • University of Sheffield (GB)
  • Sheffield Hallam University (GB)
  • Queen's University Belfast (GB)
  • University of Manchester (GB)
  • University of Liverpool (GB)
Corresponding author
Wildman, Martin J
Venue
Thorax
Publisher
BMJ
Published
2021-09-23
Volume
77
Issue
5
Pages
461-469
ISSN
  • 0040-6376 (ISSN-L)
  • 1468-3296
OpenAlex
W3198550711
Cited by
54
References
46
Citations by year
2026: 5 · 2025: 7 · 2024: 10 · 2023: 13 · 2022: 15 · 2021: 4
FWCI
6.82
Type
journal article
Language
en
Open access
Locations
  • Thorax (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Research Explorer (The University of Manchester) (acceptedVersion, cc-by)
  • SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University) (acceptedVersion)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • PEARL (University of Plymouth) (submittedVersion)
  • Research Portal (Queen's University Belfast) (submittedVersion, cc-by)
  • Science and Technology Facilities Council (submittedVersion, cc-by)
Funders
  • Programme Grants for Applied Research (RP-PG-1212-20015)
  • NHS England Commissioning for Quality and Innovation (IM2 Cystic Fibrosis Patient Adherence)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
cystic fibrosis, pulmonary exacerbations, medication adherence, self-management interventions, digital health platforms, behaviour change interventions, mucoactive agents, antibiotics, body mass index, lung function, treatment burden
MeSH terms
Self-Management, Treatment Adherence and Compliance, Adult, Cystic Fibrosis, Female, Humans, Lung, Male, Quality of Life, Respiratory Function Tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. https://app.cochat.ai/papers/10.1136/thoraxjnl-2021-217594
The paper
Wildman, M. J., O’Cathain, A., Maguire, C., Arden, M. A., Hutchings, M., Bradley, J., Walters, S. J., Whelan, P., Ainsworth, J., Buchan, I., Mandefield, L., Sutton, L., Tappenden, P., Elliott, R. A., Hoo, Z. H., Drabble, S. J., & Beever, D. (2022). Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax. https://doi.org/10.1136/thoraxjnl-2021-217594

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.